Bristol Myers’ partner Biokin says bispecific ADC clears fourth cancer trial in China
Chinese biotech Biokin said its EGFRxHER3 bispecific antibody-drug conjugate passed a late-stage China trial in a genetically-defined form…
Browsing Tag